Price
$598.16
Increased by +1.21%
Dollar volume (20D)
560.18 M
ADR%
2.90
Earnings report date
Oct 30, 2025
Shares float
97.89 M
Shares short
2.29 M [2.34%]
Shares outstanding
104.17 M
Market cap
62.64 B
Beta
0.33
Price/earnings
14.90
20D range
540.79 605.18
50D range
502.49 605.18
200D range
475.77 858.32

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy.

Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions.

It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies.

The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Reported date EPSChange YoY EstimateSurprise
Jul 30, 25 12.89
Increased by +11.51%
8.53
Increased by +51.11%
Apr 30, 25 8.22
Decreased by -13.93%
8.48
Decreased by -3.03%
Jan 31, 25 12.07
Increased by +1.77%
11.38
Increased by +6.06%
Oct 31, 24 12.46
Increased by +7.51%
11.69
Increased by +6.59%
Aug 1, 24 11.56
Increased by +12.89%
10.61
Increased by +8.95%
May 2, 24 9.55
Decreased by -5.35%
10.09
Decreased by -5.35%
Feb 2, 24 11.86
Decreased by -5.57%
10.73
Increased by +10.53%
Nov 2, 23 11.59
Increased by +4.04%
10.72
Increased by +8.12%
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 25 3.68 B
Increased by +3.62%
1.39 B
Decreased by -2.84%
Increased by +37.86%
Decreased by -6.24%
Mar 31, 25 3.03 B
Decreased by -3.70%
808.70 M
Increased by +12.01%
Increased by +26.70%
Increased by +16.31%
Dec 31, 24 3.79 B
Increased by +10.33%
917.70 M
Decreased by -20.86%
Increased by +24.22%
Decreased by -28.27%
Sep 30, 24 3.72 B
Increased by +10.65%
1.34 B
Increased by +33.02%
Increased by +36.03%
Increased by +20.22%
Jun 30, 24 3.55 B
Increased by +12.32%
1.43 B
Increased by +47.90%
Increased by +40.38%
Increased by +31.68%
Mar 31, 24 3.15 B
Decreased by -0.54%
722.00 M
Decreased by -11.71%
Increased by +22.96%
Decreased by -11.23%
Dec 31, 23 3.43 B
Increased by +0.58%
1.16 B
Decreased by -3.13%
Increased by +33.77%
Decreased by -3.69%
Sep 30, 23 3.36 B
Increased by +14.53%
1.01 B
Decreased by -23.40%
Increased by +29.97%
Decreased by -33.12%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY